EGFR and Skin rash: Focusing on toxicity in elderly patients with EGFR‐mutated NSCLC, previous studies have shown that the incidence of Grade 3 skin rash, diarrhea, and pneumonitis was 14%, 13%, and 2.9%, respectively, with afatinib [16].